Cencora disclosed that beginning July 1, 2026, certain Walgreens volume previously serviced separately from the prime vendor agreement began moving outside the Company. The company clarified that this transition was fully anticipated in its August 5, 2026 commentary regarding fourth-quarter expectations for its U.S. Healthcare Solutions segment and reaffirmed its adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026. Cencora operates as a wholesale distributor of pharmaceuticals and healthcare products.
